Clinical Trial Update: Mitoxantrone ± Cetuximab 2nd Line Androgen Independent Prostate Cancer (AIPC) [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating mitoxantrone with or without cetuximab as second-line therapy for castration-resistant prostate cancer; the study completed and results…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• ERBITUX (cetuximab)
• Novantrone (mitoxantrone)

Snippet

Sponsor: US Oncology Research | Conditions: Androgen-independent Prostate Cancer | Phase 2 | Status: COMPLETED | Results posted: 2016-12-09